Skip to search formSkip to main contentSkip to account menu

Nikavir

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
23 patients were treated with the acute stage of HIV infection for 8-48 weeks. All patients received antiretroviral therapy with… 
2018
2018
OBJECTIVES The goal of this work was to study the immunological and virological efficacy of the domestic antiretroviral drug… 
Review
2017
Review
2017
Federation Convincing evidence for high therapeutic activity and tolerability of Phosphazide in the treatment of HIV/AIDS… 
Review
2015
Review
2015
The review sums up the results of using the antiretroviral drug phosphazide (Nikavir) as a component of HAART delivered to HIV… 
2010
2010
In 2007-2008, the Perm Territorial Center for Prevention and Control of AIDS and Communicable Diseases investigated the efficacy… 
2004
2004
: Nikavir (phosphazide) is an antiretroviral agent of the class of inhibitors of type 1 HIV reverse transcriptase. It was… 
Review
2004
Review
2004
  • G. A. Galegov
  • 2004
  • Corpus ID: 21195110
Nikavir (phosphazide) is an antiretroviral agent of the class of inhibitors of type 1 HIV reverse transcriptase. It was designed… 
2003
2003
New antiviral drug "Nikavir" was clinically tested in acute hepatitis B (AHB). A total of 60 AHB patients were followed up; 30… 
2003
2003
New antiviral drug "Nikavir" was clinically tested in acute hepatitis B (AHB). A total of 60 AHB patients were followed up; 30…